Analyst Price Target is $25.33
▲ +254.31% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for GT Biopharma in the last 3 months. The average price target is $25.33, with a high forecast of $26.00 and a low forecast of $25.00. The average price target represents a 254.31% upside from the last price of $7.15.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in GT Biopharma.